Recombinant Alexa Fluor® 568 Anti-Collagen I antibody [EPR24331-53] (ab312943)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Alexa Fluor® 568 Rabbit monoclonal [EPR24331-53] to Collagen I
- Suitable for: Antibody labelling, Target binding affinity
- Conjugation: Alexa Fluor® 568. Ex: 578nm, Em: 603nm
Related conjugates and formulations
Overview
-
Product name
Alexa Fluor® 568 Anti-Collagen I antibody [EPR24331-53]
See all Collagen I primary antibodies -
Description
Alexa Fluor® 568 Rabbit monoclonal [EPR24331-53] to Collagen I -
Host species
Rabbit -
Conjugation
Alexa Fluor® 568. Ex: 578nm, Em: 603nm -
Tested applications
Suitable for: Antibody labelling, Target binding affinitymore details -
Immunogen
Synthetic peptide. This information is proprietary to Abcam and/or its suppliers.
-
General notes
This conjugated primary antibody is released using a quantitative quality control method that evaluates binding affinity post-conjugation and efficiency of antibody labeling.
For suitable applications and species reactivity, please refer to the unconjugated version of this clone. This conjugated antibody is eligible for Abtrial: learn more here.
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C. Avoid freeze / thaw cycle. Store In the Dark. -
Storage buffer
pH: 7.40
Preservative: 0.02% Sodium azide
Constituents: 30% Glycerol (glycerin, glycerine), 1% BSA, 68% PBS -
Concentration information loading...
-
Purity
Protein A purified -
Clonality
Monoclonal -
Clone number
EPR24331-53 -
Isotype
IgG -
Research areas
Associated products
-
Alternative Versions
- Anti-Collagen I antibody [EPR24331-53] (ab270993)
- Anti-Collagen I antibody [EPR24331-53] - BSA and Azide free (ab279711)
- Alexa Fluor® 488 Anti-Collagen I antibody [EPR24331-53] (ab309248)
- Alexa Fluor® 647 Anti-Collagen I antibody [EPR24331-53] (ab309367)
- APC Anti-Collagen I antibody [EPR24331-53] (ab310848)
- PE Anti-Collagen I antibody [EPR24331-53] (ab310918)
- Alexa Fluor® 555 Anti-Collagen I antibody [EPR24331-53] (ab313153)
- Alexa Fluor® 594 Anti-Collagen I antibody [EPR24331-53] (ab313351)
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab312943 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
Antibody labelling |
Use at an assay dependent concentration.
|
|
Target binding affinity |
Use at an assay dependent concentration.
|
Notes |
---|
Antibody labelling
Use at an assay dependent concentration. |
Target binding affinity
Use at an assay dependent concentration. |
Target
-
Function
Type I collagen is a member of group I collagen (fibrillar forming collagen). -
Tissue specificity
Forms the fibrils of tendon, ligaments and bones. In bones the fibrils are mineralized with calcium hydroxyapatite. -
Involvement in disease
Defects in COL1A1 are the cause of Caffey disease (CAFFD) [MIM:114000]; also known as infantile cortical hyperostosis. Caffey disease is characterized by an infantile episode of massive subperiosteal new bone formation that typically involves the diaphyses of the long bones, mandible, and clavicles. The involved bones may also appear inflamed, with painful swelling and systemic fever often accompanying the illness. The bone changes usually begin before 5 months of age and resolve before 2 years of age.
Defects in COL1A1 are a cause of Ehlers-Danlos syndrome type 1 (EDS1) [MIM:130000]; also known as Ehlers-Danlos syndrome gravis. EDS is a connective tissue disorder characterized by hyperextensible skin, atrophic cutaneous scars due to tissue fragility and joint hyperlaxity. EDS1 is the severe form of classic Ehlers-Danlos syndrome.
Defects in COL1A1 are the cause of Ehlers-Danlos syndrome type 7A (EDS7A) [MIM:130060]; also known as autosomal dominant Ehlers-Danlos syndrome type VII. EDS is a connective tissue disorder characterized by hyperextensible skin, atrophic cutaneous scars due to tissue fragility and joint hyperlaxity. EDS7A is marked by bilateral congenital hip dislocation, hyperlaxity of the joints, and recurrent partial dislocations.
Defects in COL1A1 are a cause of osteogenesis imperfecta type 1 (OI1) [MIM:166200]. A dominantly inherited connective tissue disorder characterized by bone fragility and blue sclerae. Osteogenesis imperfecta type 1 is non-deforming with normal height or mild short stature, and no dentinogenesis imperfecta.
Defects in COL1A1 are a cause of osteogenesis imperfecta type 2A (OI2A) [MIM:166210]; also known as osteogenesis imperfecta congenita. A connective tissue disorder characterized by bone fragility, with many perinatal fractures, severe bowing of long bones, undermineralization, and death in the perinatal period due to respiratory insufficiency.
Defects in COL1A1 are a cause of osteogenesis imperfecta type 3 (OI3) [MIM:259420]. A connective tissue disorder characterized by progressively deforming bones, very short stature, a triangular face, severe scoliosis, grayish sclera, and dentinogenesis imperfecta.
Defects in COL1A1 are a cause of osteogenesis imperfecta type 4 (OI4) [MIM:166220]; also known as osteogenesis imperfecta with normal sclerae. A connective tissue disorder characterized by moderately short stature, mild to moderate scoliosis, grayish or white sclera and dentinogenesis imperfecta.
Genetic variations in COL1A1 are a cause of susceptibility to osteoporosis (OSTEOP) [MIM:166710]; also known as involutional or senile osteoporosis or postmenopausal osteoporosis. Osteoporosis is characterized by reduced bone mass, disruption of bone microarchitecture without alteration in the composition of bone. Osteoporotic bones are more at risk of fracture.
Note=A chromosomal aberration involving COL1A1 is found in dermatofibrosarcoma protuberans. Translocation t(17;22)(q22;q13) with PDGF. -
Sequence similarities
Belongs to the fibrillar collagen family.
Contains 1 fibrillar collagen NC1 domain.
Contains 1 VWFC domain. -
Post-translational
modificationsProline residues at the third position of the tripeptide repeating unit (G-X-Y) are hydroxylated in some or all of the chains. Proline residues at the second position of the tripeptide repeating unit (G-X-Y) are hydroxylated in some of the chains.
O-linked glycan consists of a Glc-Gal disaccharide bound to the oxygen atom of a post-translationally added hydroxyl group. -
Cellular localization
Secreted > extracellular space > extracellular matrix. - Information by UniProt
-
Alternative names
- Alpha 1 type I collagen antibody
- Alpha 2 type I collagen antibody
- alpha 2 type I procollagen antibody
see all
Protocols
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
Datasheets and documents
-
SDS download
-
Datasheet download
References (0)
ab312943 has not yet been referenced specifically in any publications.